key: cord-0785149-pf5s9kbz
authors: Henss, Lisa; Scholz, Tatjana; von Rhein, Christine; Wieters, Imke; Borgans, Frauke; Eberhardt, Fabian J; Zacharowski, Kai; Ciesek, Sandra; Rohde, Gernot; Vehreschild, Maria; Stephan, Christoph; Wolf, Timo; Hofmann-Winkler, Heike; Scheiblauer, Heinrich; Schnierle, Barbara S
title: Analysis of humoral immune responses in SARS-CoV-2 infected patients
date: 2020-10-31
journal: J Infect Dis
DOI: 10.1093/infdis/jiaa680
sha: 56750a687576f247d535b9955b6e44b907d96db9
doc_id: 785149
cord_uid: pf5s9kbz

BACKGROUND: The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection has caused a pandemic with tens of millions of cases and hundreds of thousands of deaths. The infection causes COVID-19, a disease of the respiratory system of divergent severity. Here, the humoral immune response of a cohort of 143 COVID-19 patients from the University Hospital Frankfurt/Main, Germany was characterized. METHODS: SARS-CoV-2-specific antibodies were detected by enzyme-linked immunosorbent assay (ELISA). SARS-CoV-2 and hCoV NL63 neutralization activity was analyzed with pseudotyped lentiviral vectors. RESULTS: COVID-19 severity increased with age and male patients encountered more serious symptoms than females. Disease severity correlated with the amount of SARS-CoV-2 specific IgG and IgA and the neutralization activity of the antibodies. The amount of SARS-CoV-2 specific IgG antibodies decreased with time after PCR conformation of the infection and antibodies directed against the nucleoprotein waned faster than spike directed antibodies. In contrast, for the common flu coronavirus NL63, COVID19 disease severity seemed to correlate with low NL63-neutralizing activities, suggesting the possibility of cross-reactive protection. CONCLUSION: The results describe the humoral immune responses against SARS-CoV-2 and might aid the identification of correlates of protection needed for vaccine development.

A c c e p t e d M a n u s c r i p t 4

The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) belongs to the Coronaviridae family and is the causative agent of pneumonia, defined as corona virus disease-2019 (COVID- 19) , which first emerged in the Hubei province in China [1] . The virus rapidly spread worldwide and the SARS-CoV-2 pandemic was declared by the World Health Organization (WHO), on March 11, 2020. Coronaviruses can cause different diseases in humans. Four endemic human coronaviruses, OC43, 229E, HKU1 and NL63 are the causative agents of common colds. Two other coronaviruses, the severe acute respiratory syndrome virus (SARS-CoV) and the Middle East respiratory syndrome virus (MERS-CoV), have a high pathogenic potential with 15-30% mortality in humans and have caused small epidemics of severe pneumonia [2] .

Coronavirus serology has rapidly developed in the last few month and several commercial enzymelinked immunosorbent assay (ELISA) kits are available. The coronavirus structural proteins, the surface glycoprotein termed spike (S) and the more abundant nucleocapsid (N) are the principle immunogens used for detection of anti-SARS-CoV-2 specific antibodies [3] . The spike protein consists of two subunits S1 and S2. S1 mediates the attachment of the virus to human cells via its receptorbinding domain (RBD) and S2 mediates the fusion of the viral and cellular membranes. Antibodies that bind to the spike protein, and in particular to the RBD domain, can neutralize coronaviruses.

Recombinant RBD or S1 protein facilitates detection of coronavirus-specific antibodies by ELISA [4] .

In the current pandemic, the urgent need for effective therapeutic measures requires a profound understanding of the pathogenesis of SARS-CoV-2. Here, we analyzed the humoral immune response of German COVID-19 patients in order to characterize the disease and support the identification of correlates of protection needed for the development of vaccines and therapeutic antibodies.

A c c e p t e d M a n u s c r i p t 5

Cell culture HEK293T-hACE2 [5] and HEK293T (ATCC CRL-3216) cells were cultured at 37°C under 5% CO 2 and grown in Dulbecco's modified Eagle medium (DMEM; Sigma, Taufkirchen, Germany) supplemented with 10% fetal bovine serum (Sigma, Taufkirchen, Germany) and 5% L-glutamine (200 mM; Lonza, Verviers, Belgium) and 1% penicillin/streptavidin (Fisher Scientific, Schwerte, Germany).

Human naïve serum was obtained from the German Red Cross from volunteer blood donors and was The samples were single donations with three exceptions, the two patients with score 7 and one patient with initial score 5. The score 7 patients donated blood twice and at the second donation they improved their clinical score to score 6. The score 5 patient showed more clinical signs at the second blood donation and had a score 6. Blood samples were collected between 7 to 130 days after PCR confirmation of the infection.

Lentiviral vectors were prepared in HEK293T cells by co-transfection using Lipofectamine® 2000 (Thermo Fisher, Darmstadt, Germany) as described previously [7] . Plasmids encoding HIV-1 gag/pol, rev, the luciferase-encoding lentiviral vector genome and the SARS-CoV-2 delta 19 spike (#MN908947) or the NL63 delta 19 spike gene (#AFV53148.1) were transfected. The coronavirus genes were synthesized (Eurofins, Ebersberg, Germany) and cloned into the vector pIRES-GFP as described before [8] . Vectors were concentrated by ultracentrifugation and stored at -80°C.

Pseudotyped vectors and serially diluted human serum (1:60 to 1:14,580) were incubated in triplicates for 30 min. at 37°C and used to transduce HEK293T-hACE2 cells. After 48 hours, luciferase substrate was added to measure luciferase activity. The reciprocal area under the curve (AUC) value calculated for each sample corresponds to the neutralization activity.

The following CE marked ELISA kits used were: Liaison SARS-CoV-2 S1/S2 IgG (Diasorin SpA, Saluggia, Italy) and Architect SARS-CoV-2 IgG (Abbott GmbH, Wiesbaden, Germany). The tests were carried out and interpreted according to the manufacturers' instructions, as stated in the package inserts.

An ELISA utilizing the SARS-CoV-2 RBD as antigen was established in-house, following a protocol from Stadelbauer et al. 2020 [9] . The RBD was transiently expressed from HEK293T cells and purified A c c e p t e d M a n u s c r i p t 7 by Ni-affinity chromatography. The expression plasmid was generously provided by Florian Krammer, Icahn School of Medicine at Mount Sinai, New York, USA and is described in [9] . RDB was used to coat 96 well microtiter ELISA plates at a concentration of 2 μg/ml and antibodies directed against either human IgG (Merck, Darmstadt, Germany, Cat# 6029) or IgA (ThermoFischer, Dreieich, Germany, Cat# A18781) -horseradish-peroxidase coupled were used to detect binding antibodies.

The values obtained with samples from 5 naïve individuals and two standard derivations of these values were subtracted as cut-off. Figure 1 ). There was a significant difference in age when patients with mild to moderate disease were compared to patients with severe disease (Figure 1 ). Of the patients with clinical score 1-3, females were significantly younger with a mean age of 40.5 years than male patients, with a mean age of 45.7 years (Figure 1 ). This gender difference was not significant for patients with severe disease. However, only 8% of the patients had severe disease, which might not be representative. A total of 71 male and 75 female patients were analyzed and with one exception, only male patients had severe disease (score 5-7) ( Figure 1 ). reduces the luciferase activity. Neutralization activity of serum was determined using the area under the curve (AUC) generated by serum dilutions. Neutralization activity depicted as the reciprocal AUC increased with the severity of disease and was highest in patients with a disease score of 7 ( Fig. 2A) .

Overall, the neutralization activity of patient-derived antibodies was quite diverse, with occasional high level of neutralization activity of serum samples of patients with mild disease. However, when patients with a clinical score of 2 were analyzed for gender distribution of neutralizing antibodies, male patients had more neutralizing antibodies than females, which corresponds to the higher number of male patients with severe disease (Fig. 1)B) .

The presence of spike binding antibodies in patient serum was analyzed by an in-house ELISA coated with the SARS-CoV-2 S1 RBD according to a previously developed protocol [9] , [4] . The amount of RBD-binding IgG (Fig. 3A) and IgA (Fig. 3B) increased with the severity of disease and showed a significant increase when comparing patients with a score of 1 to those with a score of 4 -7. There were only two patients with clinical score 7 and the data might not be representative. The clinical score also correlated with the amount of S1/S2-binding IgG determined by the quantitative ELISA from Liaison (Diasorin SpA, Saluggia, Italy) (Fig. 3C ). Compared to mildly affected patients there was a significant increase in S1/S2-binding IgG detected in the serum of patients with a score of 4 and higher. This increase in IgG binding was less obvious when the Architect nucleocapsid protein (N) ELISA (Abbott GmbH, Wiesbaden, Germany) was used (Fig. 3D) , indicated by the lower significance of the difference between patients with a score of 6 and 1.

A c c e p t e d M a n u s c r i p t 10

Most patients had a clinical score of 2 (N=96); however, these single patient serum samples were collected at different time points after PCR-based diagnosis. A decrease in antibody titers, especially antibodies directed against N has been described before [10] . Therefore, the patients with this clinical score were investigated for the presence of antibodies directed against the viral N protein ( Fig 4A) and a significant decrease in antibody binding to N was observed in samples from 81-130 days after diagnosis. A similar decrease was observed for IgG directed against RBD (Fig. 4B) 

Preexisting immune responses against the common cold causing human CoVs have been described before [11] , [12] and consequently neutralization of one human CoV, NL63, by the patient material was studied. Neutralization activity was determined with lentiviral vectors pseudotyped with the NL63 spike protein and, as before, this is depicted as the reciprocal AUC (Fig. 5 ). Once again, the neutralization activity of patient-derived antibodies was quite diverse, with high neutralization activity observed for a small number of patients. However, high NL63 neutralizing activity was not detected in samples from patients with severe COVID-19 (score of 5-7) patients. However, the overall difference between the neutralization activities of patients with clinical score 1 and 2 compared to score 5-7 patients was significant (Fig. 5) .

A c c e p t e d M a n u s c r i p t 11

The analysis of 143 COVID-19 patients from the University Hospital Frankfurt/Main revealed that most patients had mild disease (78%). However, severe cases were more frequent with older patients, particularly males. The clinical score was positively correlated with SARS-CoV-2 neutralizing activity in serum samples from the patients. This was reflected by the observation, that male patients not only had increased levels of neutralizing antibodies, but also more severe disease. In addition, IgG or IgA directed against the SARS-CoV-2 spike protein or RBD and, less significantly to the N protein, correlated with disease severity. The less significant correlation shown by antibodies directed against the N protein might reflect different sensitivities in the detection assays or the transient nature of the antibody responses. Similar correlations have been observed previously by others [13] , [14] , [15] , [16] .

Among the patients with a clinical score of 2, a decrease in S-and N-directed IgG antibodies was observed in blood samples drawn at later time points after infection. This might indicate the waning of SARS-CoV-2 specific antibodies that has been described previously [17] , [18] . Longitudinal analysis of individual patients is needed to fully confirm a decline in antibody titer. Similar observations of declining antibody levels have been described for human coronaviruses. A study of individuals experimentally infected with hCoV-229E showed that levels IgG and IgA antibodies directed against the virus waned to background levels within 11 weeks to 1 year [19] .

Overall, the neutralizing titers of patients with mild disease were very low and higher titers were only detected in patients with severe disease. A reciprocal AUC value of higher than 8 corresponds to high neutralizing activity and was reached by only 5.4% of the samples. Thereby we confirm previous observations that most convalescent plasma samples obtained from individuals who recover from COVID-19 do not contain high levels of neutralizing activity [13] , [20] . Transfusion of A c c e p t e d M a n u s c r i p t 12 convalescent plasma is being considered and evaluated as a therapeutic option for the treatment of COVID-19, but the identification of suitable plasma donors is hampered by this substantial variability in levels of neutralizing antibodies in convalescent patients.

Interestingly, patients with severe disease (scores of 5-7) had no high level NL63-neutralizing antibodies, which might be related to the small number of patients that were analyzed. However, the small number of SARS-CoV-2 naïve individuals analyzed, had high NL63-neutralizing antibodies and a high seroprevalence. Serological data about NL63 infections is mainly available from children and indicate that HCoV-NL63 infections are common during childhood [21] . It is tempting to speculate that preexisting immunity to NL63 or other common cold coronaviruses might reduce the risk of severe disease. Neutralizing antibodies might only be a surrogate for this immunity, since preexisting SARS-CoV-2 T cell immunity has been described in naïve individuals [11] , [12] . Conserved peptides, with low homology among beta-coronaviruses have been recognized before and infection with human CoVs might induce a pan-coronavirus T cell immunity [11] .

Currently vaccine development mainly relies on the assumption that antibodies will be essential for protection. Protection of individuals with anti-SARS-CoV-2 antibodies has recently been described [22] . However, the minimal threshold level for protection is currently unknown. Here, we characterized the humoral immune responses of COVID-19 patients; however, the correlation of preexisting immune responses with protection is necessary for the identification of correlates of protection that will aid and accelerate vaccine development. Distribution of clinical scores of COVID-19 patients stratified by age and gender.

The age of female (f) and male (m) COVID-19 patients is indicated for patients with mild to moderate disease (score 1-3) and patients with severe disease (score 4-7). The mean age is depicted above the columns. The p-values indicate significant differences between the samples and were calculated using the Student's t-test and the GraphPad Prism 7.04 software. Ns= not significant * P ≤ 0.05; *** P ≤ 0.001. Ns= not significant P > 0.05; * P ≤ 0.05; ** P ≤ 0.01; *** P ≤ 0.001; **** P ≤ 0.0001 Ns= not significant; P > 0.05; * P ≤ 0.05; ** P ≤ 0.01; *** P ≤ 0.001; **** P ≤ 0.0001

Antibody titers of score 2 patient samples at different time points after a positive PCR test.

SARS-CoV-2 binding antibodies were determined by different ELISA assays. The p-values indicate significant differences in binding compared to initial samples obtained at the earliest time points and were calculated using the Student's t-test and the GraphPad Prism 7.04 software. Ns= not significant; P > 0.05; * P ≤ 0.05; ** P ≤ 0.01; *** P ≤ 0.001; **** P ≤ 0.0001

HCoV-NL63-neutralizing activity of serum samples from COVID-19 patients.

The NL63-neutralizing activity of serum samples was determined with NL63-pseudotyped lentiviral vectors and the reciprocal area under the curve (AUC) was plotted against the indicated clinical scores. Significant differences were detected using the Student's t-test and were calculated using the 

A new coronavirus associated with human respiratory disease in China

Origin and evolution of pathogenic coronaviruses

Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein

A serological assay to detect SARS-CoV-2 seroconversion in humans

Differential downregulation of ACE2 by the spike proteins of severe acute respiratory syndrome coronavirus and human coronavirus NL63

A minimal common outcome measure set for COVID-19 clinical research

Establishment of an Alphavirus-Specific Neutralization Assay to Distinguish Infections with Different Members of the Semliki Forest complex

A neutralization assay for chikungunya virus infections in a multiplex format

SARS-CoV-2 Seroconversion in Humans: A Detailed Protocol for a Serological Assay, Antigen Production, and Test Setup

Humoral Response Dynamics Following Infection with SARS-CoV

Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals

SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls

Convergent antibody responses to SARS-CoV-2 in convalescent individuals

SARS-CoV-2 IgG Antibody Responses

Clinical characteristics and antibody response to SARS-CoV-2 spike 1 protein using the VITROS Anti-SARS-CoV-2 antibody tests in COVID-19 patients in Japan

Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease Patients

Antibody dynamics to SARS-CoV-2 in asymptomatic COVID-19 infections

Cross-sectional evaluation of humoral responses against SARS-CoV-2 Spike

The time course of the immune response to experimental coronavirus infection of man

Neutralizing Antibody Responses in COVID-19 Convalescent Sera

We thank Heike Baumann and Julia Gerbeth for excellent technical assistance.